"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT03979898","Safety and Effectiveness of Autologous Adipose Tissue Derived Mesenchymal Stem Cell Implantation in Patients With CP","CP","Completed","No Results Available","Cerebral Palsy","Biological: ASTROSTEM","Kaufman Assessment Battery for Children (K-ABC)|Blood concentration test|Gross Motor Function Measurement (GMFM)|Box and Block Test|Modified Ashworth Scale (MAS)|SF-36|Verification of ASTROSTEM's effect on the brain through fMRI & MRS (Magnetic Resonance Spectroscopy) scan","R-Bio|Kyung Hee University Hospital at Gangdong","All","36 Months to 12 Years   (Child)","Early Phase 1","1","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","biostar-CP","June 15, 2017","April 23, 2019","May 13, 2019","June 7, 2019",,"June 7, 2019","KyungHee University Gandong Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03979898"
2,"NCT04527224","Study to Evaluate the Efficacy and Safety of AstroStem-V in Treatment of COVID-19 Pneumonia",,"Not yet recruiting","No Results Available","Covid19 Pneumonia","Drug: AstroStem-V","Incidence of adverse events|Abnormalities of physical examination, vital signs, and laboratory test|SpO2|Mortality rate|Ventilator treatment status|Improvement of pneumonia assessed by radiologic examination(Chest X-ray or CT)|SOFA score (Sequential Organ Failure Assessment)|2019 nCOV nucleic acid test","Nature Cell Co. Ltd.","All","19 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","10","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ASVP1N2A-US","October 1, 2022","November 1, 2023","December 1, 2023","August 26, 2020",,"September 28, 2022","Medical Advancement Center of Arizona, Phoenix, Arizona, United States|Epic Medical Research, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04527224"
3,"NCT04482413","Study to Evaluate the Safety and Efficacy of AstroStem in Treatment of Alzheimer's Disease",,"Not yet recruiting","No Results Available","Alzheimer Disease","Drug: AstroStem|Drug: Placebo","SUVR (Standard Uptake Value Ratio)|CDR-SB score (Clinical Dementia Rating Sum of Boxes)|ADAS-Cog-11 score (Alzheimer's Disease assessment Scale-Cognitive Subscale (11 items))|MMSE (Mini-mental status examination)|ADCS-ADL-MCI (Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory)|C-SSRS (Columbia Suicide Severity Rating Scale)|NPI (Neuropsychiatric Inventory)|Treatment related Adverse Events","Nature Cell Co. Ltd.","All","50 Years and older   (Adult, Older Adult)","Phase 2","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","AST-ADP2-US02","February 1, 2023","May 30, 2024","December 20, 2024","July 22, 2020",,"September 28, 2022",,,"https://ClinicalTrials.gov/show/NCT04482413"
4,"NCT03117738","A Study to Evaluate the Safety and Efficacy of AstroStem in Treatment of Alzheimer's Disease",,"Completed","Has Results","Alzheimer Disease","Drug: AstroStem|Other: Placebo-Control","Treatment Related Adverse Events|ADAS-Cog (Alzheimer's Disease Assessment Scale-cognitive Subscale)|MMSE (Mini-mental Status Examination)|CDR-SOB (Clinical Dementia Rating-Sum of Boxes)|NPI (Neuropsychiatric Inventory)|GDS (Geriatric Depression Scale)|ADCS-ADL (Alzheimer's Disease Cooperative Study Activities of Daily Living)|C-SSRS (Columbia Suicide Severity Rating Scale)","Nature Cell Co. Ltd.","All","50 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","21","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AST-ADP2-US01","May 9, 2017","June 26, 2019","August 31, 2019","April 18, 2017","July 9, 2021","August 10, 2021","ATP Clinical Research, Costa Mesa, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|Valden Medical, Honolulu, Hawaii, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT03117738/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT03117738/SAP_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT03117738/ICF_002.pdf","https://ClinicalTrials.gov/show/NCT03117738"
5,"NCT01274975","Autologous Adipose Derived MSCs Transplantation in Patient With Spinal Cord Injury.","MSC","Completed","No Results Available","Spinal Cord Injury","Other: Autologous Adipose Derived Mesenchymal Stem Cells","safety evaluation","R-Bio","Male","19 Years to 60 Years   (Adult)","Phase 1","8","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Astrostem","July 2009","November 2009","February 2010","January 12, 2011",,"March 26, 2014",,,"https://ClinicalTrials.gov/show/NCT01274975"
